
Chemomab Therapeutics
(NASDAQ) CMMB
Chemomab Therapeutics Financials at a Glance
Market Cap
$10.94M
Revenue (TTM)
$0.00
Net Income (TTM)
-$7.46M
EPS (TTM)
-$1.11
P/E Ratio
-1.37
Dividend
$0.00
Beta (Volatility)
1.11 (Average)
Dividend
$0.00
Beta (Volatility)
1.11 (Average)
Price
$1.51
Volume
62,094
Open
$1.50
Price
$1.51
Volume
62,094
Open
$1.50
Previous Close
$1.52
Daily Range
$1.50 - $1.63
52-Week Range
$1.35 - $5.00
Estimated Earnings Date
Aug 7, 2026
Dividend
$0.00
Beta (Volatility)
1.11 (Average)
Price
$1.51
Volume
62,094
Open
$1.50
Previous Close
$1.52
Daily Range
$1.50 - $1.63
52-Week Range
$1.35 - $5.00
Estimated Earnings Date
Aug 7, 2026
CMMB News
Motley Fool Moneyball Superscore
Our CEO Is Handing Members His Secret Weapon
It's called Motley Fool Moneyball, our new proprietary AI tool
We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.
Get Access NowAbout Chemomab Therapeutics
Industry
Biotechnology
Sector
Health CareEmployees
12
CEO
Adi Mor, PhD
Website
www.chemomab.comHeadquarters
Tel Aviv, 6158002, IL
CMMB Financials
Key Financial Metrics (TTM)
Gross Margin
0%
Operating Margin
0%
Net Income Margin
0%
Return on Equity
-71%
Return on Capital
-74%
Return on Assets
-63%
Earnings Yield
-72.99%
Dividend Yield
0.00%
Payout Ratio
0.00%
Stock Overview
Market Cap
$10.94M
Shares Outstanding
7.20M
Volume
62.09K
Avg. Volume
45.26K
Financials (TTM)
Gross Profit
$0.00
Operating Income
-$9.57M
EBITDA
-$9.50M
Operating Cash Flow
-$11.22M
Capital Expenditure
-$3.03K
Free Cash Flow
-$11.22M
Cash & ST Invst.
$10.37M
Total Debt
$0.00
Chemomab Therapeutics Performance Analysis
Revenue Growth Rate
Annual and quarterly growth comparisonCurrently no data to display.
Earnings Per Share Growth Rate
Annual and quarterly EPS growth comparisonQuarterly Performance
Revenue
$0.00
N/A
Gross Profit
$0.00
N/A
Gross Margin
0.00%
N/A
Market Cap
$10.94M
N/A
Market Cap/Employee
$547.23K
N/A
Employees
20
N/A
Net Income
-$1.77M
+46.6%
EBITDA
-$1.85M
+46.7%
Quarterly Fundamentals
Total Cash
$8.04M
-23.9%
Total Debt
$0.00
-100.0%
Accounts Receivable
$3.43M
+169.3%
Inventory
$0.00
N/A
Long Term Debt
$0.00
-100.0%
Short Term Debt
$0.00
-100.0%
Return on Assets
-63.15%
N/A
Return on Invested Capital
-74.26%
N/A
Free Cash Flow
-$11.22M
N/A
Operating Cash Flow
-$11.22M
N/A